Indivior CSO sells 18,586 shares under trading plan

Indivior Pharmaceuticals, Inc. reports that Chief Scientific Officer Christian Heidbreder conducted an open-market sale of 18,586 shares of common stock at $41.14 per share on July 10, 2026.

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reports that Chief Scientific Officer Christian Heidbreder conducted an open-market sale of 18,586 shares of common stock at $41.14 per share on July 10, 2026. Following this transaction, he holds 209,337 shares directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.

Filing Explained

The July 10 sale reduced the Chief Scientific Officer’s direct holdings to 209,337 shares under a plan adopted March 13.

A Form 4 reports an insider transaction to the SEC. The July 13 filing records Christian Heidbreder, Indivior’s Chief Scientific Officer, selling 18,586 common shares on 2026-07-10 at $41.14 per share, leaving 209,337 shares held directly; the structural change is to the reporting person’s disclosed ownership.

Transaction code S identifies an open-market sale, and the filing says the sale was effected under a Rule 10b5-1 trading plan adopted on 2026-03-13. A Rule 10b5-1 plan is written in advance to execute trades on a schedule or formula; the filing provides the plan’s adoption date, not the reasons for this individual trade.

The platform’s 90-day insider history records three sales totaling 73,172 shares and no purchases, including this July 10 sale.

Insider Trade Summary 10b5-1

Net Seller: 18,586 shares

Net Sell 1 txn

Insider Heidbreder Christian

Role Chief Scientific Officer

Sold 18,586 shs ($765K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	18,586	$41.14	$765K

Holdings After Transaction: Common Stock — 209,337 shares (Direct)

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

Key Figures

Shares Sold: 18,586 shares Sale Price: $41.14 per share Shares Held After Transaction: 209,337 shares +1 more

4 metrics

Shares Sold 18,586 shares Open-market sale of common stock on July 10, 2026

Sale Price $41.14 per share Price received in the July 10, 2026 open-market sale

Shares Held After Transaction 209,337 shares Direct ownership by the CSO following the reported sale

10b5-1 Plan Adoption Date March 13, 2026 Date the Rule 10b5-1 trading plan governing the sale was adopted

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"The reported security title is Common Stock of Indivior Pharmaceuticals, Inc."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) disclose for Christian Heidbreder?

Indivior disclosed that Chief Scientific Officer Christian Heidbreder executed an open-market sale of 18,586 shares of common stock on July 10, 2026, at a price of $41.14 per share under a Rule 10b5-1 trading plan.

How many Indivior (INDV) shares did the CSO sell and at what price?

Chief Scientific Officer Christian Heidbreder sold 18,586 shares of Indivior common stock at $41.14 per share. The transaction is reported as an open-market sale of non-derivative common stock.

How many Indivior (INDV) shares does the CSO hold after the July 2026 sale?

After the reported transaction, Chief Scientific Officer Christian Heidbreder holds 209,337 shares of Indivior common stock directly. This figure reflects his ownership immediately following the July 10, 2026 open-market sale.

Was the Indivior (INDV) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026, indicating the trades were pre-arranged rather than discretionary.

What role does the insider have at Indivior (INDV) in this Form 4 filing?

The reporting person, Christian Heidbreder, is identified as Indivior’s Chief Scientific Officer. The Form 4 covers his direct ownership and the reported open-market sale of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heidbreder Christian

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VIRGINIA 23235

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		S(1)		18,586	D	$41.14	209,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

Remarks:

	/s/Alice Givens, Power of Attorney	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)